The diagnostic value of 14-3-3η protein levels in patients with rheumatoid arthritis

Publication date: Available online 21 February 2019Source: Best Practice & Research Clinical RheumatologyAuthor(s): O. Shovman, B. Gilburd, A. Watad, H. Amital, P. Langevitz, N.L. Bragazzi, M. Adawi, D. Perez, G. Bornstein, C. Grossman, M. Lidar, M. Blank, J. Azuri, N.K. Biln, A. Marotta, Y. ShoenfeldAbstract14-3-3η may represent a useful diagnostic biomarker for rheumatoid arthritis (RA). We assessed the prevalence and serum levels of 14-3-3η in patients with RA and in patients with other rheumatic diseases.Serum levels of 14-3-3η were measured in 96 patients with RA, in 101 patients with other rheumatic diseases, and in 66 healthy subjects. All of the sera samples were evaluated by JOINT stat 14-3-3η ELISA test kits (Augurex Life Sciences Corp.).Median (IQR) 14-3-3η levels were significantly higher in the early RA group [0.25 ng/ml (0.075–3.11)] and in patients with established RA [0.15 ng/ml (0.08–1.26)] than in healthy subjects [0 ng/ml (0-0)] and disease controls: SLE [0.01 ng/ml (0–0.055)], AS [0.05 ng/ml (0–0.255)], and PsA [0.01 ng/ml (0–0.065)].The prevalence of 14-3-3η positivity in patients with early RA was 58%, significantly higher than that in disease controls and healthy subjects (p < 0.001). In patients with established RA, this prevalence was 43%, and it was significantly higher than that in patients with other rheumatic diseases and healthy subjects (p < 0.05), excluding the AS group (p = 0.054).In the early RA cohort, the...
Source: Best Practice and Research Clinical Rheumatology - Category: Rheumatology Source Type: research